PARTNERSHIPS AND COLLABORATIONS
In 2018, Micregen's product development potential was recognised by the UK’s science and research national funding agency, UK Research and Innovation. Micregen was awarded an Innovate UK Smart grant toward the development of MRG1061, the company’s product targeting Necrotising Enterocolitis.
Funding was provided through the Government’s modern industrial strategy by Innovate UK, part of UK Research and Innovation.
UK Research and Innovation is a new organisation that brings together the UK Research Councils, Innovate UK and Research England into a single organisation to create the best environment for research and innovation to flourish. The vision is to ensure the UK maintains its world-leading position in research and innovation.
We are proud to work with leading specialists in our target areas of interest.
The Hospital for Sick Children (SickKids), affiliated with the University of Toronto, is Canada's most research-intensive hospital and the largest centre dedicated to improving children's health in the country. As innovators in child health, SickKids improves the health of children by integrating care, research and teaching. With a staff that includes professionals from all disciplines of health care and research, SickKids provides the best in complex and specialized care by creating scientific and clinical advancements, sharing knowledge and expertise and championing the development of an accessible, comprehensive and sustainable child health system.
SickKids are working with Micregen on various pre-clinical models for paediatric conditions.
The Hospital for Sick Children (SickKids), affiliated with the University of Toronto, is Canada's most research-intensive hospital and the largest centre dedicated to improving children's health in the country. In 2021 Newsweek named SickKids as the No.1 Paediatric Hospital in the world. As innovators in child health, SickKids improves the health of children by integrating care, research and teaching. With a staff that includes professionals from all disciplines of health care and research, SickKids provides the best in complex and specialized care by creating scientific and clinical advancements, sharing knowledge and expertise and championing the development of an accessible, comprehensive and sustainable child health system.
SickKids are working with Micregen on various pre-clinical models for paediatric conditions.
Together, Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH) have been at the forefront of many breakthroughs in children’s medicine and their work has benefited the lives of children all over the world.
The new Zayed centre provides much needed dedicated laboratories, cutting-edge technology and equipment, and offices for up to 400 world-leading scientists and clinicians. The Zayed Centre for Research brings together expertise from GOSH, ICH and the UCL Institute of Cardiovascular Science under one roof for the first time. This unique partnership forms the largest concentration of paediatric research and clinical expertise in Europe.
The strategic positioning of the new centre and its proximity to both GOSH and ICH is vital for a truly translational and patient-focussed approach to research, building on existing strengths and bringing together teams to embody their bench-to-bedside model.
GOSH are collaborating with Micregen to complete an important part of the MRG1061 production process to provide the therapeutic to be utilised in paediatric clinical trials.
Together, Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH) have been at the forefront of many breakthroughs in children’s medicine and their work has benefited the lives of children all over the world.
The new Zayed centre provides much needed dedicated laboratories, cutting-edge technology and equipment, and offices for up to 400 world-leading scientists and clinicians. The Zayed Centre for Research brings together expertise from GOSH, ICH and the UCL Institute of Cardiovascular Science under one roof for the first time. This unique partnership forms the largest concentration of paediatric research and clinical expertise in Europe.
The strategic positioning of the new centre and its proximity to both GOSH and ICH is vital for a truly translational and patient-focussed approach to research, building on existing strengths and bringing together teams to embody their bench-to-bedside model.
GOSH are collaborating with Micregen to complete an important part of the MRG1061 production process to provide the therapeutic to be utilised in paediatric clinical trials. In 2021 Newsweek named GOSH as the No.4 Paediatric Hospital in the world.
The University of Bradford are collaborating with Micregen on studying the validation of a Secretomix as a therapeutic for Neurodegeneration. The studies have been designed to determine efficacy of Secretomix in models of Frontotemporal Dementia, Alzheimers Disease, Parkinson’s Disease and Motor Neurone disease.
The University of Bradford are collaborating with Micregen on studying the validation of a Secretomix as a therapeutic for Neurodegeneration. The studies have been designed to determine efficacy of Secretomix in models of Frontotemporal Dementia, Alzheimers Disease, Parkinson’s Disease and Motor Neurone Disease.
